이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PharmaResearch 미래 성장

Future 기준 확인 4/6

PharmaResearch (는) 각각 연간 20.9% 및 16.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 21.1% 로 예상됩니다.

주요 정보

20.9%

수익 성장률

19.8%

EPS 성장률

Biotechs 수익 성장	51.0%
매출 성장률	16.6%
향후 자기자본 수익률	21.1%
애널리스트 커버리지	Low
마지막 업데이트	19 Jun 2024

최근 미래 성장 업데이트

Recent updates

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

May 21

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25

수익 및 매출 성장 예측

KOSDAQ:A214450 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	446,661	139,095	136,000	141,200	3
12/31/2025	374,740	114,027	91,750	122,833	4
12/31/2024	322,833	97,060	92,000	100,650	3
3/31/2024	280,285	76,092	70,589	85,849	N/A
12/31/2023	261,011	76,551	52,260	64,945	N/A
9/30/2023	244,661	64,902	41,817	53,239	N/A
6/30/2023	222,030	55,615	43,861	57,280	N/A
3/31/2023	204,932	48,964	46,461	61,734	N/A
12/31/2022	194,759	40,577	41,686	59,404	N/A
9/30/2022	183,191	46,501	43,484	65,744	N/A
6/30/2022	175,719	42,366	42,071	65,573	N/A
3/31/2022	164,813	43,752	38,455	62,868	N/A
12/31/2021	154,083	46,689	41,866	65,297	N/A
9/30/2021	143,282	47,110	36,738	58,386	N/A
6/30/2021	133,706	41,534	7,076	45,944	N/A
3/31/2021	122,609	40,153	6,042	43,936	N/A
12/31/2020	108,746	32,774	-2,991	32,392	N/A
9/30/2020	101,282	27,003	-4,928	27,003	N/A
6/30/2020	91,747	23,109	13,967	23,521	N/A
3/31/2020	84,091	16,407	11,603	18,946	N/A
12/31/2019	83,872	16,667	9,489	19,272	N/A
9/30/2019	77,416	19,060	250	12,948	N/A
6/30/2019	73,324	16,384	-7,794	13,176	N/A
3/31/2019	70,242	15,310	-12,069	8,818	N/A
12/31/2018	64,281	14,408	-19,414	5,203	N/A
9/30/2018	61,865	6,913	-13,353	6,975	N/A
6/30/2018	60,777	11,134	-9,967	7,070	N/A
3/31/2018	56,519	12,579	-9,865	5,562	N/A
12/31/2017	54,470	12,956	N/A	8,555	N/A
9/30/2017	50,615	14,522	N/A	8,312	N/A
6/30/2017	47,241	13,472	N/A	6,052	N/A
3/31/2017	46,580	14,378	N/A	7,680	N/A
12/31/2016	45,953	13,909	N/A	8,161	N/A
9/30/2016	45,092	16,725	N/A	10,507	N/A
12/31/2015	37,455	12,878	N/A	16,023	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A214450 의 연간 예상 수익 증가율( 20.9% )이 saving rate( 2.5% 보다 높습니다. ).

수익 vs 시장: A214450 의 연간 수익( 20.9% ) KR 시장( 28.8% 보다 느리게 성장할 것으로 예상됩니다. 28.8% 연간).

고성장 수익: A214450 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: A214450 의 수익(연간 16.6% ) KR 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: A214450 의 수익(연간 16.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A214450 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 21.1 %)

PharmaResearch 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 7.1% to ₩187,500

Price target increased by 19% to ₩158,750

Price target increased by 11% to ₩107,500

Price target decreased to ₩88,300

Consensus forecasts updated

Price target decreased to ₩96,500

Recent updates

New minor risk - Share price stability

New minor risk - Shareholder dilution

Price target increased by 7.1% to ₩187,500

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 18%

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Full year 2023 earnings released: EPS: ₩7,571 (vs ₩4,067 in FY 2022)

Upcoming dividend of ₩660 per share at 0.6% yield

Price target increased by 19% to ₩158,750

Investor sentiment improves as stock rises 15%

Now 20% undervalued

New minor risk - Shareholder dilution

Now 20% undervalued

Price target increased by 11% to ₩107,500

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 20%

Now 21% undervalued

Price target decreased to ₩88,300

Upcoming dividend of ₩600 per share

Consensus forecasts updated

Price target decreased to ₩96,500

Price target decreased to ₩100,000

Consensus forecasts updated

Price target increased to ₩112,500

Upcoming dividend of ₩500 per share

PharmaResearch Co., Ltd. (KOSDAQ:A214450) acquired Medicoson Co., Ltd.

Price target increased to ₩120,000

Consensus revenue estimates increase to ₩152.8m

Price target increased to ₩88,100

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

New 90-day high: ₩64,900

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

New 90-day low: ₩53,900

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

New 90-day low: ₩56,100

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

New 90-day low: ₩57,600

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Third quarter 2020 earnings released: EPS ₩812

Price target raised to ₩78,433

New 90-day high - ₩63,300

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견